Place of PARP inhibitors in the treatment of endometrial and cervical cancers

xlomafota13 shared this article with you from Inoreader Place of PARP inhibitors in the treatment of endometrial and cervical cancers Via Association française pour l'étude du cancer Bull Cancer. 2021 Nov 17:S0007-4551(21)00425-2. doi: 10.1016/j.bulcan.2021.09.011. Online ahead of print. ABSTRACT New molecular therapeutic approaches have emerged in recent years for advanced gynaecological cancers, including targeted therapies such as poly-ADP-ribose polymerase inhibitors (PARPi). These have demonstrated efficacy in high-grade serous ovarian cancers in patients carrying a mutation in the BRCA gene, which predisposes them to breast and ovarian cancers. Clinical and pre-clinical data suggest that the activity of PARPi inhibitors may not be limited to BRCA mutated tumours and may involve the homologous recombination pathway. These data raise the question of the potential efficacy of PARPi in advanced endometrial and cervical cancers where treatment options are currently limited. At present, there are few data available on the activity of PARPi in endometrial and cervical cancers, but some results seem promising. In thi s review, we present a synthesis of the available studies concerning PARPi in endometrial and cervical cancer. PMID:34801228 | DOI:10.1016/j.bulcan.2021.09.011 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.